Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing

Loading news article.

Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing | WAPE

Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing

Article summary

Related companies

Analyzed by WAPE AI.

Comments —